Oppenheimer analyst Suraj Kalia downgraded ResMed (NYSE: RMD) from Outperform to Perform.The analyst comments "SURMOUNT-OSA dataset was presented at ADA ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE